On behalf of subsidiaries-Norley Corporation Inc.: Capital injection to Steady Way Limited US$ 25,750,000 to purchase a Kamsarmax bulker.

On behalf of subsidiaries-Norley Corporation Inc.: Capital injection to Steady Way Limited US$ 25,750,000 to purchase a Kamsarmax bulker.
1.Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.):
Capital injection by cash
2.Date of occurrence of the event:2022/10/21
3.Amount, unit price, and total monetary amount of the transaction: 
No par value, US$ 25,750,000
4.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the 
trading counterparty is not required to be disclosed):
Steady Way Limited, 100% of shares owned by Norley Corporation Inc.
5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the 
previous owner, its relationship with the Company and the trading counterparty, and the 
previous date and monetary amount of transfer:N/A
6.Where an owner of the underlying assets within the past five years has been a related 
party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors' rights (including types of 
collaterals of the disposed creditor’s rights; if creditor's rights over a related 
party, announcement shall be made of the name of the related party and the book amount 
of the creditor's rights, currently being disposed of, over such related party):N/A
8.Profit or loss from the disposal (not applicable in cases of acquisition of securities) 
(those with deferral should provide a table explaining recognition):N/A
9.Terms of delivery or payment (including payment period and monetary amount), restrictive 
covenants in the contract, and other important terms and conditions:
Authorize directors to decide terms of delivery or payment.
10.The manner of deciding on this transaction (such as invitation to tender, price 
comparison, or price negotiation), the reference basis for the decision on price, 
and the decision-making unit: The Board of Directors.
11.Net worth per share of the Company's underlying securities acquired or disposed of:N/A
12.Cumulative no.of shares held (including the current transaction), their monetary amount, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment: 500 shares, US$25,750,000, 100% of shares, without restricted.
13.Current ratio of securities investment (including the current trade, as listed in article 3 of Regulations Governing the Acquisition and Disposal of Assets by Public Companies) to 
the total assets and equity attributable to owners of the parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as 
of the present:
Ratio of the total asset: 3.88%
Ratio of equity attributable to owners of the parent: 5.48%
Working capital of the parent: NTD 3,283,924 thousand.
14.Broker and broker's fee:N/A
15.Concrete purpose or use of the acquisition or disposal: Purchase a Kamsarmax bulker.
16.Any dissenting opinions of directors to the present transaction: N/A
17.Whether the counterparty of the current transaction is a related party:No.
18.Date of the board of directors resolution:NA
19.Date of ratification by supervisors or approval by the Audit Committee:NA
20.Whether the CPA issued an unreasonable opinion regarding the current transaction:N/A
21.Name of the CPA firm:N/A
22.Name of the CPA:N/A
23.Practice certificate number of the CPA:N/A
24.Whether the transaction involved in change of business model:No.
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past year and the expected coming 
year:N/A
27.Source of funds:N/A
28.Any other matters that need to be specified:None.